Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gisslinger

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|March 2, 2017
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaH Gisslinger, G Jeryczynski, B Gisslinger, et al.
Leukemia|December 30, 2015
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaH Gisslinger, G Jeryczynski, B Gisslinger, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Leukemia|September 20, 2011
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaG Finazzi, A Carobbio, J Thiele, et al.
Leukemia|May 15, 2009
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia veraD Olcaydu, R C Skoda, R Looser, et al.
Leukemia|October 25, 2016
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceA Tefferi, H K Al-Ali, G Barosi, et al.
Blood Cancer Journal|December 1, 2015
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaT Barbui, A M Vannucchi, V Buxhofer-Ausch, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|March 2, 2017
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaH Gisslinger, G Jeryczynski, B Gisslinger, et al.
Leukemia|December 30, 2015
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaH Gisslinger, G Jeryczynski, B Gisslinger, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Leukemia|September 20, 2011
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaG Finazzi, A Carobbio, J Thiele, et al.
Leukemia|May 15, 2009
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia veraD Olcaydu, R C Skoda, R Looser, et al.
Leukemia|October 25, 2016
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceA Tefferi, H K Al-Ali, G Barosi, et al.
Blood Cancer Journal|December 1, 2015
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaT Barbui, A M Vannucchi, V Buxhofer-Ausch, et al.
Pageof 10